Opendata, web and dolomites

MEXOM SIGNED

Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEXOM project word cloud

Explore the words cloud of the MEXOM project. It provides you a very rough idea of what is the project "MEXOM" about.

vitro    effect    disability    immunomodulatory    vital    entrepreneurship    brain    exert    worldwide    molecular    clinical    deleterious    preclinical    policymakers    world    innovation    glp    mature    plays    gmp    secreted    ex    acquire    cord    vesicles    intellectual    biology    micrornas    inflammation    candidate    evs    transferable    first    inflammatory    small    treatment    experiments    independent    failed    clinically    communication    reinforce    anti    skills    cell    stroke    transfer    innovations    unmet    host    action    property    models    human    demonstrated    scientist    assurance    fellowship    molecule    competences    researcher    academia    receive    cells    enrichment    public    msc    quality    training    boosted    applicable    medical    acute    advancing    societies    private    cargo    mechanism    career    extracellular    leader    indicate    regulations    stem    molecules    mesenchymal    he    civil    stakeholders    vivo    mscs    data    regenerative    manufacturing    preconditioning    ischemic    grade    highlight    industry    medicine    commercial    time   

Project "MEXOM" data sheet

The following table provides information about the project.

Coordinator
THE CELL-FACTORY 

Organization address
address: GALILEILAAN 19
city: NIEL
postcode: 2845
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-09-03   to  2020-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CELL-FACTORY BE (NIEL) coordinator 160˙800.00

Map

 Project objective

Stroke is leading cause of long-term disability in Europe and worldwide with no effective treatment so far. Inflammation plays a vital role in brain’s response to ischemic stroke with deleterious consequences during early acute phase. Strong immunomodulatory effect of human mesenchymal stem cell (MSCs) demonstrated in many preclinical stroke models, however, has failed in clinical experiments. Recent preclinical data indicate that MSCs exert their anti-inflammatory effects via secreted extracellular vesicles (EVs) through microRNAs and this potential could be boosted by preconditioning MSCs ex vivo with small molecules. The aim of this Fellowship will be the determination of MSC-EVs anti-inflammatory mechanism of action specific for stroke for the first time.

The Host has developed clinical-grade technology (GLP/GMP) for human cord MSC-EVs manufacturing at large scale with anti-inflammatory action. During this Project the Researcher will receive training-through-research and will investigate the small molecule potential impact on MSC-EVs cargo enrichment with specific microRNAs. Then he will study candidate microRNAs anti-inflammatory potential in vitro on the key brain inflammation cells. The Researcher will acquire transferable knowledge in regulations, quality assurance, intellectual property and entrepreneurship. Novel competences will reinforce the Researcher as mature and independent scientist in the field of regenerative medicine with new career opportunities in private sector. Communication and dissemination will be carried out with all stakeholders, including academia, industry, civil societies, policymakers and general public.

The Researcher will transfer his molecular biology knowledge and skills, thus advancing the development of MSC-EVs product for treatment of stroke at the Host towards clinically applicable commercial innovation. This Fellowship will highlight Europe as world leader in innovations targeting unmet medical needs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEXOM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEXOM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NotToKill-NotToDie (2019)

Unrevealing dry season Plasmodium falciparum replication biology

Read More  

PARTOWNEU (2019)

The dark side of partial ownership and financial investment in Europe: What price to pay for consumers and society?

Read More  

HYMNS (2020)

Hypothalamic Modulation of Neocortical States

Read More